Trials / Unknown
UnknownNCT04164459
Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.
A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase IV Study to Evaluate the Efficacy and Safety of Xalost S in Glaucoma Patients.
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- Sponsor
- Taejoon Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
In patients with Glaucoma, Xalost S or Xalatan or Taflotan-S are administered for 12 weeks. After 12 weeks, among them, Xalatan administration group are switched to Xalost S or Taflotan-S. Extension study period is 8 weeks. To compare effect (ocular surface damage) and safety of preservative-free Latanoprost/Tafluprost to Benzalkonium chloride-preserved Latanoprost in primary open angle glaucoma or normal tension glaucoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xalost S | One drop one times a day in study eye |
| DRUG | Xalatan | One drop one times a day in study eye |
| DRUG | Taflotan-S | One drop one times a day in study eye |
Timeline
- Start date
- 2018-12-19
- Primary completion
- 2019-12-01
- Completion
- 2020-02-01
- First posted
- 2019-11-15
- Last updated
- 2019-11-15
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04164459. Inclusion in this directory is not an endorsement.